Back
Compare AU
Compare DRUG vs. DJRE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the State Street SPDR Dow Jones Gbl Real Estate Esg Tilted ETF (DJRE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | DJRE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 128 |
Median incremental investment | $740.50 | $1,046.08 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,783.28 | $4,231.14 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | DJRE | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | DJRE.AX was created on 2013-11-01 by State Street . The fund's investment portfolio concentrates primarily on real estate equity. The ETF currently has 524.53m in AUM and 223 holdings. The State Street SPDR Dow Jones Global Real Estate ESG Tilted ETF seeks to closely track, before fees and expenses, the returns of the Dow Jones Global Select ESG Tilted Real Estate Securities Index. |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | Prologis Inc (8.52 %) Welltower Inc (7.48 %) Public Storage (6.54 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Real Estate (100.00 %) Other (5.20 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | United States (71.31 %) Japan (9.05 %) United Kingdom of Great Britain and Northern Ireland (3.07 %) |
Management fee | 0.57 % | 0.2 % |
Key Summary
DRUG | DJRE | |
|---|---|---|
Issuer | BetaShares | State Street |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Dow Jones Global Select ESG Tilted Real Estate Securities Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.2 % |
Price | $8.85 | $21.81 |
Size | $179.004 million | $522.856 million |
10Y return | N/A | 4.65 % |
Annual distribution yield (5Y) | 1.92 % | 3.62 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 04/11/2013 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | DJRE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 128 |
Median incremental investment | $740.50 | $1,046.08 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,783.28 | $4,231.14 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | DJRE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | DJRE |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |